U.S. flag An official website of the United States government.
Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Advisory Committee on Immunization Practices (ACIP)

CDC Stacks Public Health Publications

The ACIP is a group of medical and public health experts that develops recommendations on the use of vaccines in the civilian population of the United States. The ACIP holds three meetings each year at the Centers for Disease Control and Prevention (CDC), in Atlanta, Georgia to make vaccine recommendations. Meetings are open to the public and available online via webcast. More information on ACIP is available at: https://www.cdc.gov/vaccines/acip/index.html.

(93)
(134)
(234)
(272)
(175)
(108)
(133)
(111)
(96)
(79)
(115)
(115)
(125)
(16)
(23)
(16)
(18)
(13)
(17)
(9)
(8)
(15)
(11)
(6)
(10)
(10)
(5)
(10)
(11)
(5)
(8)
(9)
(6)
(9)
(8)
(7)
(6)
(10)
(5)
(6)
(5)
(6)
(6)
(5)
(5)
(6)
(9)
(3)
(8)
(4)
(3)
(2)
(5)
(3)
(2)
(4)
(3)
(3)
(2)
(2)
(1)
0 of 61
(12)
(32)
(108)
(35)
(11)
(1)
(1)
(48)
(48)
(49)
(7)
(1293)
(463)
(7)
0 of 14
(1)
(1)
(1)
(4)
(2)
(1)
(1)
(2)
(6)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(6)
(1)
(1)
(5)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(406)
(1)
(1)
(1)
(1)
(1)
(1)
0 of 46
(1)
(1)
(1)
0 of 3
(10)
(5)
(1)
(4)
(2)
(3)
(1)
(5)
(1)
(2)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(126)
(1)
(146)
(1)
(33)
(66)
(1)
(1)
(62)
(14)
(2)
(3)
(18)
(1)
(4)
(1)
(1)
(1)
(2)
(31)
(2)
(3)
(1)
(1)
(3)
(6)
(1)
(1)
(10)
(1)
(3)
(2)
(2)
(14)
(2)
(2)
(3)
(5)
(2)
(1)
(9)
(3)
(1)
(2)
(2)
(4)
(1)
(1)
(1)
(1)
(5)
(3)
(1)
(7)
(1)
(10)
(1)
(1)
(10)
(1)
(2)
(1)
(1)
(2)
(1)
(1)
(7)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(3)
(1)
(9)
(1)
(1)
(1)
(12)
(1)
(2)
(1)
(3)
(9)
(1)
(6)
(1)
(3)
(10)
(1)
(1)
(1)
(1)
(1)
(2)
(3)
(3)
(1)
(11)
(2)
(2)
(4)
(1)
(3)
(13)
(8)
(153)
(106)
(2)
(2)
(1)
(1)
(11)
(2)
(1)
(10)
(2)
(7)
(2)
(1)
(1)
(1)
(7)
(15)
(4)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(20)
(5)
(197)
(44)
(5)
(4)
(1)
(19)
(2)
(2)
(82)
(2)
(257)
(6)
(21)
(2)
(1)
(3)
(1)
(1)
(8)
(1)
(4)
(2)
(1)
(1)
(117)
(7)
(5)
(3)
(1)
(1)
(1)
(3)
(1)
(1)
(3)
(35)
(2)
(1)
(16)
(2)
(12)
(1)
(32)
(2)
(2)
(1)
(1)
(1)
(3)
(22)
(1)
(2)
(2)
(10)
(2)
(2)
(2)
(3)
(1)
(1)
(2)
(23)
(10)
(3)
(5)
(1)
(1)
(15)
(1)
(3)
(1)
(9)
(1)
(2)
(2)
(1)
(1)
(2)
(2)
(1)
(4)
(1)
(1)
(17)
(1)
(1)
(1)
(2)
(1)
(2)
(1)
(1)
(3)
(2)
(1)
(2)
(1)
(5)
(1)
(1)
(2)
(2)
(1)
(4)
(1)
(9)
(2)
(5)
(1)
(1)
(1)
(1)
(1)
(1)
(51)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(21)
(3)
(1)
(5)
(1)
(15)
(1)
(56)
(1)
(2)
(5)
(2)
(2)
(1)
(1)
(3)
(5)
(2)
(1)
(15)
(1)
(1)
(2)
(2)
(1)
(3)
(1)
(33)
(2)
(1)
(3)
(2)
(2)
(1)
(19)
(2)
(2)
(4)
(4)
(2)
(1)
(1)
(2)
(5)
(5)
(1)
(1)
(1)
(7)
(9)
(9)
(1)
(1)
(3)
(1)
(26)
(3)
(1)
(2)
(1)
(1)
(10)
(1)
(2)
(1)
(1)
(39)
(2)
(1)
(1)
(1)
(3)
(4)
(1)
(2)
(3)
(1)
(35)
(1)
(1)
(1)
(7)
(1)
(6)
(2)
(10)
(11)
(1)
(1)
(6)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(165)
(5)
(1)
(1)
(4)
(343)
(1)
(6)
(3)
(76)
(2)
(2)
(1)
(1)
(1)
(2)
(50)
(6)
(4)
(321)
(1)
(1)
(1)
(192)
(1)
(2)
(17)
(3)
(2)
(3)
(3)
(1)
(1)
(1)
(1)
(6)
(6)
(104)
(1)
(69)
(1)
(5)
(2)
(3)
(2)
(1)
(1)
(39)
(1)
(1)
(10)
(1)
(11)
(4)
(25)
(15)
(2)
(1)
(2)
(1)
(3)
(10)
(4)
(15)
(2)
(13)
(2)
(18)
(6)
(2)
(1)
(1)
(2)
(2)
(4)
(172)
(18)
(2)
(1)
(11)
(5)
(2)
(2)
(2)
(1)
(1)
(1)
(2)
(2)
(2)
(2)
(2)
(2)
(2)
(3)
(1)
(1)
(1)
(1)
(12)
(3)
(2)
(4)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(10)
(1)
(4)
(1)
(1)
(31)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(5)
(3)
(2)
(6)
(1)
(13)
(2)
(2)
(2)
(1)
(1)
(1)
(1)
(1)
(40)
(1)
(2)
(8)
(1)
(11)
(1)
(1)
(6)
(28)
(1)
(1)
(1)
(2)
(1)
(7)
(1)
(9)
(1)
(1)
(1)
(2)
(1)
(2)
(4)
(1)
(1)
(3)
(14)
(3)
(1)
(10)
(2)
(1)
(104)
(1)
(1)
(1)
(1)
(1)
(1)
(61)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(10)
(1)
(3)
(4)
(14)
(1)
(12)
(3)
(4)
(3)
(1)
(6)
(1)
(7)
(1)
(1)
(5)
(1)
(13)
(2)
(1)
(1)
(1)
(1)
(1)
(5)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(4)
(1)
(7)
(1)
(3)
(6)
(2)
(1)
(2)
(1)
(2)
(1)
(7)
(1)
(1)
(1)
(2)
(1)
(1)
(29)
(152)
(5)
(1)
(1)
(1)
(3)
(2)
(55)
(1)
(1)
(34)
(1)
(8)
(1)
(1)
(56)
(2)
(1)
(6)
(1)
(1)
(1)
(35)
(2)
(1)
(2)
(1)
(1)
(6)
(1)
(1)
(1)
(1)
(1)
(17)
(1)
(1)
(8)
(1)
(91)
(3)
(1)
(2)
(4)
(1)
(1)
(11)
(2)
(3)
(1)
(3)
(1)
(4)
(2)
(6)
(2)
(2)
(1)
(8)
(2)
(1)
(5)
(1)
(10)
(12)
(1)
(6)
(1)
(1)
(1)
(6)
(1)
(35)
(1)
(9)
(1)
(62)
(6)
(3)
(2)
(1)
(1)
(1)
(2)
(1)
(26)
(1)
(1)
(1)
(1)
(1)
(3)
(3)
(1)
(16)
(1)
(1)
(1)
(4)
(2)
(14)
(1)
(1)
(4)
(3)
(2)
(12)
(1)
(1)
(4)
(5)
(2)
(1)
(11)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(10)
(6)
(2)
(1)
(49)
(13)
(8)
(48)
(8)
(2)
(13)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(4)
(18)
(12)
(1)
(1)
(3)
(9)
(1)
(2)
(1)
(3)
(1)
(1)
(1)
(1)
(1)
(1)
(5)
(32)
(5)
(2)
(13)
(5)
(1)
(1)
(2)
(19)
(1)
(6)
(2)
(1)
(2)
(1)
(2)
(2)
(1)
(1)
(3)
(2)
(1)
(4)
(2)
(1)
(1)
(2)
(1)
(1)
(26)
(2)
(2)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(11)
(1)
(2)
(1)
(2)
(1)
(3)
(2)
(6)
(1)
(5)
(4)
(8)
(5)
(1)
(1)
(21)
(1)
(1)
(2)
(7)
(3)
(2)
(2)
(2)
(1)
(2)
(1)
(1)
(630)
(17)
(2)
(1)
(1)
(5)
(1)
(1)
(24)
(22)
(4)
(4)
(1)
(13)
(379)
(1)
(28)
(23)
(23)
(1)
(1)
(1)
(21)
(1)
(1)
(1)
(1)
(1)
(1)
(9)
(2)
(1)
(1)
(51)
(2)
(1)
(11)
(1)
(1)
(18)
(1)
(2)
(1)
(2)
(5)
(3)
(1)
(1)
(12)
(1)
(2)
(170)
(2)
(1)
(1)
(1)
(1)
(21)
(1)
(1)
(10)
(1)
(1)
(4)
(1)
(1)
(2)
(1)
(1)
(2)
(1)
(2)
(1)
(11)
(2)
(1)
(2)
(1)
(2)
(1)
(2)
(1)
(33)
(1)
(2)
(4)
0 of 940
(1)
(1)
(1)
(3)
(2)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(3)
(1)
(2)
(1)
(2)
(1)
(1)
(1)
(3)
(2)
(1)
(1)
(1)
(7)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(7)
(1)
(9)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(39)
(2)
(1)
(8)
(16)
(1)
(4)
(4)
(2)
(3)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(4)
(2)
(1)
(1)
(3)
(23)
(1)
(1)
(8)
(2)
(1)
(11)
(1)
(1)
(1)
(15)
(1)
(1)
(14)
(1)
(1)
(5)
(1)
(2)
(1)
(1)
(3)
(8)
(21)
(1)
(1)
(9)
(1)
(3)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(16)
(2)
(1)
(1)
(1)
(1)
(4)
(1)
(1)
(1)
(1)
(9)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(10)
(1)
(1)
(2)
(7)
(1)
(1)
(5)
(1)
(8)
(2)
(5)
(10)
(2)
(1)
(1)
(2)
(2)
(2)
(22)
(3)
(4)
(4)
(4)
(3)
(1)
(22)
(1)
(7)
(1)
(4)
(2)
(2)
(4)
(4)
(2)
(32)
(2)
(1)
(1)
(1)
(6)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(3)
(1)
(31)
(3)
(1)
(5)
(1)
(1)
(2)
(1)
(1)
(1)
(3)
(1)
(2)
(1)
(7)
(1)
(4)
(1)
(1)
(4)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(4)
(2)
(2)
(3)
(1)
(7)
(1)
(2)
(1)
(1)
(10)
(10)
(1)
(11)
(2)
(6)
(1)
(1)
(2)
(1)
(2)
(1)
(1)
(2)
(1)
(1)
(9)
(4)
(2)
(1)
(1)
(1)
(5)
(8)
(1)
(2)
(1)
(5)
(7)
(1)
(1)
(1)
(3)
(2)
(2)
(1)
(12)
(1)
(2)
(5)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(5)
(1)
(1)
(2)
(1)
(51)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(2)
(1)
(1)
(4)
(2)
(1)
(15)
(1)
(4)
(8)
(2)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(4)
(7)
(1)
(3)
(3)
(1)
(4)
(4)
(1)
(1)
(3)
(5)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(14)
(20)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(2)
(2)
(12)
(1)
(1)
(1)
(1)
(9)
(1)
(8)
(1)
(1)
(1)
(1)
(1)
(2)
(8)
(1)
(1)
(1)
(2)
(3)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(7)
(1)
(11)
(1)
(2)
(2)
(1)
(1)
(1)
(13)
(1)
(1)
(1)
(1)
(6)
(1)
(1)
(7)
(2)
(1)
(1)
(1)
(4)
(3)
(1)
(1)
(1)
(1)
(11)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(7)
(21)
(1)
(2)
(1)
(3)
(7)
(3)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(15)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(34)
(2)
(1)
(2)
(8)
(3)
(1)
(1)
(1)
(1)
(2)
(1)
(15)
(1)
(1)
(1)
(5)
(1)
(13)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(7)
(1)
(9)
(1)
(1)
(1)
(1)
(1)
(1)
(7)
(1)
(14)
(9)
(1)
(1)
(1)
(2)
(1)
(4)
(1)
(1)
(1)
(1)
(1)
(3)
(11)
(1)
(37)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(8)
(1)
(1)
(1)
(4)
(2)
(10)
(1)
(8)
(1)
(1)
(1)
(1)
(1)
(5)
(1)
(5)
(3)
(2)
(2)
(1)
(1)
(4)
(6)
(8)
(1)
(6)
(1)
(2)
(1)
(3)
(5)
(2)
(4)
(2)
(5)
(1)
(1)
(2)
(1)
(1)
(1)
(2)
(1)
(5)
(1)
(11)
(2)
(1)
(3)
(1)
(4)
(2)
(1)
(12)
(2)
(2)
(6)
(1)
(1)
(9)
(2)
(1)
(2)
(1)
(7)
(7)
(1)
(1)
(2)
(1)
(11)
(8)
(1)
(2)
(2)
(1)
(1)
(1)
(1)
(3)
(54)
(2)
(4)
(4)
(1)
(1)
(2)
(1)
(3)
(1)
(1)
(6)
(9)
(3)
(1)
(1)
(1)
(1)
(2)
(2)
(3)
(1)
(1)
(4)
(1)
(3)
(1)
(1)
(6)
(3)
(2)
(2)
(1)
(1)
(1)
(4)
(7)
(2)
(4)
(1)
(8)
(1)
(1)
(25)
(1)
(1)
(10)
(17)
(1)
(2)
(1)
(1)
(2)
(1)
(1)
(6)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(14)
(4)
(3)
(2)
(1)
(2)
(1)
(2)
(1)
(1)
(1)
(18)
(1)
(2)
(1)
(1)
(7)
(1)
(2)
(10)
(1)
(1)
(1)
(1)
(30)
(2)
(2)
(2)
(1)
(1)
(1)
(1)
(2)
(3)
(2)
(1)
(3)
(1)
(2)
(1)
(19)
(1)
(2)
(2)
(1)
(1)
(1)
(1)
(1)
(8)
(1)
(30)
(5)
(1)
(11)
(3)
(1)
(1)
(2)
(1)
(2)
(2)
(8)
(1)
(1)
(1)
(1)
(1)
(7)
(4)
(2)
(1)
(4)
(2)
(1)
(2)
(1)
(4)
(1)
(1)
(1)
(1)
(2)
(1)
(8)
(2)
(1)
(1)
(2)
(45)
(1)
(1)
(7)
(1)
(1)
(3)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(5)
(10)
(1)
(1)
(1)
(10)
(1)
(1)
(13)
(1)
(8)
(7)
(1)
(2)
(1)
(8)
(8)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(7)
(8)
(2)
(1)
(32)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(10)
(1)
(1)
(1)
(2)
(1)
(3)
(5)
(4)
(1)
(2)
(2)
(1)
(1)
(9)
(2)
(2)
(10)
(1)
(1)
(1)
(2)
(1)
(5)
(1)
(1)
(4)
(2)
(2)
(26)
(1)
(1)
(24)
(1)
(1)
(1)
(3)
(1)
(1)
(2)
(4)
(5)
(2)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(5)
(4)
(2)
(2)
(1)
(1)
(11)
(3)
(1)
(4)
(1)
(1)
(5)
(1)
(2)
(9)
(1)
(1)
(6)
(2)
(1)
(3)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(1)
(2)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
0 of 899
(2)
(1)
(1)
(3)
(1)
(1)
(2)
(2)
(5)
(24)
(3)
(4)
(6)
(1)
(16)
(21)
(9)
(1)
(1)
(1)
(1)
(6)
(3)
(1)
(4)
(2)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(3)
(1)
(8)
(1)
(3)
(6)
(1)
(1)
(2)
(14)
(1)
(1)
(1)
(1)
(2)
(1)
(2)
(29)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(2)
(50)
(113)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(9)
(1)
(1)
(1)
(5)
(1)
(1)
(1)
(1)
(1)
(6)
(1)
(1)
(2)
(2)
(9)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(2)
(1)
(1)
(2)
(4)
(1)
(1)
(1)
(5)
(1)
(11)
(1)
(2)
(1)
(1)
(4)
(2)
(1)
(1)
(1)
(1)
(4)
(2)
(1)
(1)
(1)
(6)
(1)
(1)
(8)
(1)
(2)
(7)
(5)
(1)
(1)
(5)
(2)
(6)
(1)
(1)
(1)
(12)
(1)
(9)
(2)
(1)
(5)
(3)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(5)
(4)
(3)
(4)
(1)
(16)
(11)
(1)
(8)
(6)
(1)
(3)
(1)
(5)
(1)
(3)
(25)
(3)
(8)
(1)
(1)
(1)
(30)
(4)
(6)
(1)
(12)
(34)
(30)
(1)
(1)
(1)
(4)
(1)
(1)
(1)
(9)
(1)
(10)
(14)
(2)
(10)
(1)
(90)
(1)
(1)
(1)
(1)
(1)
(1)
(7)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(46)
(4)
(3)
(2)
(66)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(83)
(1)
(1)
(1)
(2)
(53)
(1)
(1)
(1)
(4)
(1)
(1)
(1)
(3)
(2)
(6)
(9)
(1)
(10)
(1)
(1)
(2)
(3)
(6)
(2)
(1)
(5)
(4)
(1)
(3)
(2)
(1)
(1)
(13)
(4)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(10)
(1)
(22)
(3)
(7)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(4)
(1)
(1)
(1)
(4)
(9)
(1)
(2)
(1)
(1)
(1)
(3)
(1)
(2)
(3)
(3)
(1)
(2)
(10)
(1)
(6)
(1)
(1)
(11)
(1)
(1)
(1)
(1)
(3)
(1)
(7)
(1)
(1)
(1)
(1)
(1)
(13)
(1)
(14)
(547)
(1)
(1)
(1)
(6)
(1)
(3)
(1)
(4)
(10)
(1)
(15)
(11)
(14)
(1)
(4)
(4)
(1)
(2)
(2)
(5)
(1)
(4)
(1)
(162)
(1)
(5)
(1)
(3)
(7)
(3)
(1)
(33)
(2)
(14)
(3)
(3)
(9)
(2)
(1)
(10)
(1)
(2)
(30)
(6)
(1)
(4)
(4)
(5)
(2)
(7)
(1)
(6)
(2)
(1)
(19)
(15)
(1)
(1)
(9)
(5)
(1)
(2)
(2)
(18)
(3)
(5)
(46)
(2)
(1)
(2)
(3)
(2)
(1)
(3)
(4)
(1)
(5)
(1)
(1)
(4)
(3)
(1)
(1)
(7)
(2)
(2)
(3)
(1)
(1)
(1)
(2)
(1)
(1)
(2)
(3)
(7)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(10)
(3)
(2)
(3)
(1)
(1)
(1)
(5)
(1)
(1)
(1)
(1)
(1)
(11)
(1)
(1)
(1)
(3)
(1)
(2)
(1)
0 of 464
(1)
(74)
(1)
(1)
(1624)
(32)
(7)
(8)
(1)
(14)
(102)
(200)
(10)
(12)
(32)
(1295)
(1)
(18)
(2)
(2)
(38)
(1)
(1)
(1)
0 of 24
(1)
(1)
(1)
(1)
(1)
(1)
0 of 6
(1)
0 of 1
Showing 561 - 580 of 2154 results
  • Evidence to recommendation framework PfizerBioNTech COVID19 vaccine Comirnaty
    Evidence to recommendation framework : Pfizer-BioNTech COVID-19 vaccine, Comirnaty
    Dooling, Kathleen
    August 30, 2021 | ACIP: Coronavirus Disease 2019 (COVID-19)
    08-COVID-Dooling-508.pdf
    Public Domain
  • Rapid cycle analysis to monitor the safety of COVID19 vaccines in near realtime within the Vaccine Safety Datalink Myocarditis and anaphylaxis
    Rapid cycle analysis to monitor the safety of COVID-19 vaccines in near real-time within the Vaccine Safety Datalink : Myocarditis and anaphylaxis
    Klein, Nicola P.
    August 30, 2021 | ACIP: Coronavirus Disease 2019 (COVID-19)
    04-COVID-Klein-508.pdf
    Public Domain
  • Framework for booster doses of COVID19 vaccines
    Framework for booster doses of COVID-19 vaccines
    Oliver, Sara E.
    August 30, 2021 | ACIP: Coronavirus Disease 2019 (COVID-19)
    09-COVID-Oliver-508.pdf
    Public Domain
  • COVID19 Vaccine Safety Technical VaST Work Group
    COVID-19 Vaccine Safety Technical (VaST) Work Group
    Lee, Grace M. ;
    Hopkins, Robert H.
    August 30, 2021 | ACIP: Coronavirus Disease 2019 (COVID-19)
    05-COVID-Lee-508.pdf
    Public Domain
  • Grading of recommendations assessment development and evaluation GRADE Pfizer BioNTech COVID19 vaccine
    Grading of recommendations, assessment, development, and evaluation (GRADE) : Pfizer BioNTech COVID-19 vaccine
    Gargano, Julia W.
    August 30, 2021 | ACIP: Coronavirus Disease 2019 (COVID-19)
    07-COVID-Gargano-508.pdf
    Public Domain
  • Myopericarditis following COVID19 vaccination Updates from the Vaccine Adverse Event Reporting System VAERS
    Myopericarditis following COVID-19 vaccination : Updates from the Vaccine Adverse Event Reporting System (VAERS)
    Su, John R.
    August 30, 2021 | ACIP: Coronavirus Disease 2019 (COVID-19)
    03-COVID-Su-508.pdf
    Public Domain
  • ACIP COVID19 Vaccines Work Group
    ACIP COVID-19 Vaccines Work Group
    Daley, Matt F.
    August 30, 2021 | ACIP: Coronavirus Disease 2019 (COVID-19)
    01-COVID-Daley-508.pdf
    Public Domain
  • Meeting of the Advisory Committee on Immunization Practices ACIP August 30 2021 summary minutes
    Meeting of the Advisory Committee on Immunization Practices (ACIP), August 30, 2021, summary minutes
    United States. Advisory Committee on Immunization Practices.
    08/30/2021 | ACIP Meetings Minutes
    Summary Minutes, August 30, 2021
    Public Domain
  • 19 BLA Safety and Efficacy Data For ACIP
    -19 BLA Safety and Efficacy Data For ACIP
    United States. Advisory Committee on Immunization Practices.
    08/30/2021
    ACIP meeting COVID-19 Vaccines
    Public Domain
  • PfizerBioNTech COVID19 vaccine and myocarditis in individuals aged 1629 years Benefitsrisk discussion
    Pfizer-BioNTech COVID-19 vaccine and myocarditis in individuals aged 16-29 years : Benefits-risk discussion
    Rosenblum, Hannah
    August 30, 2021 | ACIP: Coronavirus Disease 2019 (COVID-19)
    06-COVID-Rosenblum-508.pdf
    Public Domain
  • Agenda Meeting of the Advisory Committee on Immunization Practices ACIP August 30 2021 Atlanta Georgia
    [Agenda] : Meeting of the Advisory Committee on Immunization Practices (ACIP) : August 30, 2021, Atlanta, Georgia
    United States. Advisory Committee on Immunization Practices. COVID-19 Vaccines Work Group.
    August 30, 2021 | ACIP: Meeting Agenda, Minutes, etc.
    Final - August 30, 2021agenda-2021-08-30-508.pdf
    Public Domain
  • Considerations for booster doses of COVID19 vaccines
    Considerations for booster doses of COVID-19 vaccines
    Oliver, Sara E.
    08/13/2021 | ACIP: Coronavirus Disease 2019 (COVID-19)
    05-COVID-Oliver-508.pdf
    Public Domain
  • Update on emerging SARSCoV2 variants and COVID19 vaccines
    Update on emerging SARS-CoV-2 variants and COVID-19 vaccines
    Scobie, Heather
    08/13/2021 | ACIP: Coronavirus Disease 2019 (COVID-19)
    04-COVID-Scobie-508.pdf
    Public Domain
  • Clinical considerations for use of an additional mRNA COVID19 vaccine dose after a primary mRNA COVID19 vaccine series for immunocompromised people
    Clinical considerations for use of an additional mRNA COVID-19 vaccine dose after a primary mRNA COVID-19 vaccine series for immunocompromised people
    Goswami, Neela D.
    08/13/2021 | ACIP: Coronavirus Disease 2019 (COVID-19)
    03-COVID-Goswami-508.pdf
    Public Domain
  • ACIP COVID19 Vaccines Work Group
    ACIP COVID-19 Vaccines Work Group
    Daley, Matt F.
    08/13/2021 | ACIP: Coronavirus Disease 2019 (COVID-19)
    01-COVID-Daley-508.pdf
    Public Domain
  • Evidence to recommendation framework an additional dose of mRNA COVID19 vaccine following a primary series in immunocompromised people
    Evidence to recommendation framework : an additional dose of mRNA COVID-19 vaccine following a primary series in immunocompromised people
    Dooling, Kathleen
    08/13/2021 | ACIP: Coronavirus Disease 2019 (COVID-19)
    02-COVID-Dooling-508.pdf
    Public Domain
  • Agenda Meeting of the Advisory Committee on Immunization Practices ACIP August 13 2021 Atlanta Georgia
    [Agenda] : Meeting of the Advisory Committee on Immunization Practices (ACIP) : August 13, 2021, Atlanta, Georgia
    United States. Advisory Committee on Immunization Practices. COVID-19 Vaccines Work Group.
    August 12, 2021 | ACIP: Meeting Agenda, Minutes, etc.
    Final - August 12, 2021agenda-2021-08-13-508.pdf
    Public Domain
  • Use of COVID19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen Johnson Johnson and MRNA COVID19 Vaccines PfizerBioNTech and Moderna Update From the Advisory Committee on Immunization Practices United States July 2021
    Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and MRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update From the Advisory Committee on Immunization Practices — United States, July 2021
    Rosenblum, Hannah G. ;
    Hadler, Stephen C.
    August 10, 2021 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    What is already known about this topic? Rare serious adverse events have been reported after COVID-19 vaccination, including Guillain-Barré syndrome (GBS) and thrombosis with thrombocytopenia syndrome (TTS) after Janssen COVID-19 vaccination and myocarditis after mRNA (Pfizer-BioNTech and Moderna) COVID-19 vaccination.What is added by this report? ...
    Supporting Files Public Domain
  • General best practice guidelines for immunization best practices guidance of the Advisory Committee on Immunization Practices ACIP
    General best practice guidelines for immunization : best practices guidance of the Advisory Committee on Immunization Practices (ACIP)
    United States, Advisory Committee on Immunization Practices.  ...
    August 5, 2021
    The Centers for Disease Control and Prevention (CDC) recommends routine vaccination to prevent 17 vaccine-preventable diseases that occur in infants, children, adolescents, or adults. This report provides information for clinicians and other health care providers about concerns that commonly arise when vaccinating persons of various ages. Providers ...
    Superseded Public Domain
  • Benefits and risks of COVID19 vaccines Work Group considerations
    Benefits and risks of COVID-19 vaccines : Work Group considerations
    Mbaeyi, Sarah A
    07/22/2021 | ACIP: Coronavirus Disease 2019 (COVID-19)
    06-COVID-Mbaeyi-508.pdf
    Public Domain
561 - 580 / 2154